January 23, 2006
Neuroptix Announces Successful Angel Investment Round Led by Launchpad Venture Group
In vivo Alzheimer's and prion disease diagnostics company raises funds for further commercialization
Acton, Massachussetts - January 23, 2006 - Neuroptix Corporation, a Massachusetts-based Alzheimer's and prion disease diagnostics company, today announced that it had received $500,000 in angel funds to help further commercialize the company's offerings.
The investment, led by Launchpad Venture Group, included several angel groups and individuals, is intended to support on-going equipment trials. It will also be used to further develop and market Neuroptix's products assisting in the objective diagnosis and management of Alzheimer's and other degenerative neurological and ophthalmologic disorders.
Neuroptix's target market includes biopharmaceutical therapeutic and healthcare diagnostic and imaging companies.
Launchpad Venture Group member Dr. Richard D. Gill said, "Launchpad Venture Group and our investor syndicate is delighted to provide Neuroptix with the necessary financial runway to further their value proposition and move the technology towards commercial fruition."
Paul Hartung, President and CEO of Neuroptix, said "We are very pleased and excited by the prospects for commercialization of our non-invasive Alzheimer's Disease and prion disease diagnostic technologies. This investment will help us achieve our business development goals."
Participants in this financing included Launchpad Ventures, Granite State Angels, The Breakfast Club, Maine Angels, and other private investors.
About Launchpad Venture Group
Launchpad Venture Group is a Boston-based angel investment group that provides funding to early-stage companies. We are looking for innovative, technology-driven startup companies addressing a significant market opportunity where our investment can make a difference.
Today, Launchpad has over 45 active investors. Members come from a variety of backgrounds and professions, including the technology, financial and service communities. As a group, we are well connected to potential customers, service providers, partners and future sources of financing.
About Neuroptix Corporation
Founded in 2001, Neuroptix develops, manufactures and distributes state-of-the-art products for extremely sensitive measurements of biophysical changes in the eye, including a non-invasive instrument (Optiscan QEL 2400) for diagnosis and monitoring Alzheimer's disease that is now undergoing clinical study. Adaptable and innovative, Neuroptix' products are designed for a variety of research environments including academic and pharmaceutical laboratories. Neuroptix is also developing imaging compounds for application in screening tests for Alzheimer's disease and prion diseases. For more information, contact firstname.lastname@example.org or visit the web site at http://www.neuroptix.com.
# # #